Vosaroxin
Names | |
---|---|
IUPAC name
7-[(3S,4S)-3-Methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid | |
Other names
Voreloxin | |
Identifiers | |
175414-77-4 | |
3D model (Jmol) | Interactive image |
ChemSpider | 8128494 |
PubChem | 9952884 |
| |
| |
Properties | |
C18H19N5O4S | |
Molar mass | 401.44 g·mol−1 |
Density | 1.5±0.1 g/cm3 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Infobox references | |
Vosaroxin (AG-7352, SPC-595, SNS 595, voreloxin) is a topoisomerase II inhibitor causing site-selective DNA damage.It is under phase III clinical trial investigation for acute myelogenous leukemia (AML) and ovarian cancer sponsored by Sunesis.[1]
Mechanism of action
Vosaroxin is a naphthyridine analog of the anticancer quinolone derivatives (AQDs), a class of compounds that has not been used previously for the treatment of cancer. Topoisomerase II enzymes are essential for the survival of eukaryotic cells. Vosaroxin hinders the reunion of topoisomerase II-induced double-strand breaks at selective sites in DNA, resulting in G2 arrest and cell death by apoptosis.[2]
References
- ↑ "Vosaroxin". Selleck Chemicals.
- ↑ "Vosaroxin (Formerly Voreloxin)". Sunesis.
This article is issued from Wikipedia - version of the 11/16/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.